Q-Pam Relanium en es it fr

Q-Pam Relanium Brand names, Q-Pam Relanium Analogs

Q-Pam Relanium Brand Names Mixture

  • No information avaliable

Q-Pam Relanium Chemical_Formula


Q-Pam Relanium RX_link


Q-Pam Relanium fda sheet

Q-Pam Relanium msds (material safety sheet)

Q-Pam_Relanium MSDS

Q-Pam Relanium Synthesis Reference

Reeder, Sternbach; U.S. Pat. 3,371,085 (1968)

Q-Pam Relanium Molecular Weight

284.74 g/mol

Q-Pam Relanium Melting Point


Q-Pam Relanium H2O Solubility

Slightly soluble (50 mg/L)

Q-Pam Relanium State


Q-Pam Relanium LogP


Q-Pam Relanium Dosage Forms

Tablets; Injectable solution

Q-Pam Relanium Indication

Used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome.

Q-Pam Relanium Pharmacology

Diazepam, a benzodiazepine, generates the same active metabolite as chlordiazepoxide and clorazepate. In animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with diazepam do have a transient ataxia at higher doses. Diazepam was found to have transient cardiovascular depressor effects in dogs. Long-term experiments in rats revealed no disturbances of endocrine function. Injections into animals have produced localized irritation of tissue surrounding injection sites and some thickening of veins after intravenous use.

Q-Pam Relanium Absorption

Essentially complete, with a bioavailability of 93%.

Q-Pam Relanium side effects and Toxicity

Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.

Q-Pam Relanium Patient Information

Q-Pam Relanium Organisms Affected

Humans and other mammals